Context Abciximab infusion and uncoated-stent implantation is a complementary treatment
strategy to reduce major adverse cardiac events in patients undergoing angioplasty for ST …

ContextBare-metal stenting with abciximab pretreatment is currently considered a
reasonable reperfusion strategy for acute ST-segment elevation myocardial infarction …

Objectives: The aim of the study was to perform a meta-analysis of randomized trials (RTs)
comparing abciximab versus small molecules (eptifibatide and tirofiban) in primary …

Background As compared with thrombolytic therapy, primary percutaneous transluminal
coronary angioplasty (PTCA) in acute myocardial infarction reduces the rates of death …

Background—The impact on survival of routine use of abciximab as adjunctive treatment to
routine infarct artery stenting for acute myocardial infarction is not defined. We sought to …

Objectives: We sought to evaluate the efficacy of abciximab as adjunctive therapy to routine
infarct-related artery (IRA) stenting. Background: The impact of abciximab on the efficacy of …

Background Two placebo-controlled trials testing intravenous platelet glycoprotein IIb/IIIa
antagonists in the setting of percutaneous coronary revascularisation with intracoronary …

OBJECTIVE: To evaluate the efficacy and safety of abciximab following acute myocardial
infarction (AMI) treated with percutaneous coronary interventions. METHODS: A meta …

Objectives: We sought to investigate whether the previously reported midterm clinical benefit
of planned sirolimus-eluting stent (SES) implantation in patients with ST-segment elevation …

Background—Trials of platelet glycoprotein IIb/IIIa inhibitors as adjuncts to primary
percutaneous coronary intervention for acute myocardial infarction (MI) have shown …